SCIENCE@home

Tumour suppressor TRIM33 targets nuclear β-catenin degradation

Jianfei Xue,Yaohui Chen,Yamei Wu,Zhongyong Wang,Aidong Zhou,Sicong Zhang,Kangyu Lin,K. Aldape,S. Majumder,Zhimin Lu,Suyun Huang

Published 2014 in Nature Communications

ABSTRACT

Aberrant activation of β-catenin in the nucleus has been implicated in a variety of human cancers, but the fate of nuclear β-catenin is unknown. Here we demonstrate that the tripartite motif-containing protein 33 (TRIM33), acting as an E3 ubiquitin ligase, reduces the abundance of nuclear β-catenin protein. TRIM33-mediated β-catenin is destabilized and is GSK-3β or β-TrCP independent. TRIM33 interacts with and ubiquitylates nuclear β-catenin. Moreover, protein kinase Cδ, which directly phosphorylates β-catenin at Ser715, is required for the TRIM33–β-catenin interaction. The function of TRIM33 in suppressing tumour cell proliferation and brain tumour development depends on TRIM33-promoted β-catenin degradation. In human glioblastoma specimens, endogenous TRIM33 levels are inversely correlated with β-catenin. In summary, our findings identify TRIM33 as a tumour suppressor that can abolish tumour cell proliferation and tumorigenesis by degrading nuclear β-catenin. This work suggests a new therapeutic strategy against human cancers caused by aberrant activation of β-catenin. Aberrant activation of β-catenin in the nucleus has been implicated in several cancers, but the mechanisms regulating nuclear β-catenin are not well understood. Here the authors identify Trim33 as new E3 ligase targeting nuclear β-catenin independently of Wnt signal.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-49 of 49 references · Page 1 of 1

CITED BY

Showing 1-100 of 167 citing papers · Page 1 of 2

12
Next